GLP–2(3–33) acts as a competitive antagonist of the glucagon-like peptide-2 (GLP-2) receptor. It is primarily used in research settings to block the effects of endogenous GLP-2, helping scientists study the physiological roles of the GLP-2 signaling pathway. This compound is especially valuable in investigations related to intestinal growth, nutrient absorption, and gut barrier function. It has been applied in animal models to explore conditions such as short bowel syndrome, inflammatory bowel disease, and intestinal injury, where GLP-2 activity plays a protective or regenerative role. By inhibiting GLP-2 receptor activation, GLP–2(3–33) allows researchers to assess the therapeutic potential of enhancing or suppressing this pathway.